Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR58611A for prevention of depression relapse
NCT00345098Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of amibegron in major depressive disorder (MDD), sponsored by Sanofi. Started May 2006; status: completed.
02
Drugs
amibegron
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00345098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00345098.